NCT03530371View on ClinicalTrials.gov

Intranasal Dexmedetomidine for Sedated Hearing Testing

PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 2, 2019

Primary Completion Date

November 16, 2021

Study Completion Date

December 31, 2021

Conditions
Auditory Brainstem Response
Interventions
DRUG

Dexmedetomidine Hydrochloride

intranasal administration of 2.5µg/kg of dexmedetomidine to fall asleep the patients

Trial Locations (1)

06200

Hôpitaux pédiatriques de Nice CHU-Lenval, Nice

All Listed Sponsors
lead

Fondation Lenval

OTHER

NCT03530371 - Intranasal Dexmedetomidine for Sedated Hearing Testing | Biotech Hunter | Biotech Hunter